Search / Trial NCT00001123

A Collaborative Double-Blind Placebo-Controlled Trial of Intravenous Ribavirin As a Treatment for Presumed Hantavirus Pulmonary Syndrome

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001

Trial Information

Current as of October 18, 2024

Completed

Keywords

Description

Patients are randomized to receive either ribavirin or a placebo for 7 days. At the completion of therapy, patients will be seen on follow-up visits on days 14, 28, and 84.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • You may be eligible for this study if you:
  • * Are 12 years of age or older.
  • * Are not pregnant.
  • * Agree to practice sexual abstinence or use accepted barrier methods of birth control/contraception.
  • * Are not breast-feeding.
  • * Have a positive blood test for hantavirus.
  • * Have symptoms suggestive of hantavirus illness.
  • Exclusion Criteria:
  • You will not be eligible for this study if you:
  • * Have severe low blood count (anemia).
  • * Have a diagnosis of other respiratory viruses (influenza, RSV, etc.).
  • * Have group A Streptococcus with symptoms of streptococcal pharyngitis, a positive culture from a normally sterile site, or symptoms of bacterial pneumonia.
  • * Are HIV positive.
  • * Have cancer.
  • * Have had any period of irregular heartbeat.
  • * Have had chemotherapy or other drugs that suppress the immune system within 30 days.
  • * Have taken by mouth or injection any antiviral drug (other than acyclovir, famciclovir, amantadine or rimantadine.)
  • * Have taken by mouth or injection corticosteroids equivalent to approximately 0.5 mg/kg prednisone.
  • * Have taken any experimental drug within 30 days prior to enrollment.

About National Institute Of Allergy And Infectious Diseases (Niaid)

The National Institute of Allergy and Infectious Diseases (NIAID) is a key component of the National Institutes of Health (NIH) dedicated to advancing the understanding, prevention, and treatment of infectious and immune-mediated diseases. Through rigorous clinical trials, NIAID aims to foster innovative research that enhances public health and addresses global health challenges, including emerging infectious diseases and allergies. The institute collaborates with various partners, including academic institutions, industry, and international organizations, to translate scientific discoveries into effective therapies and vaccines. NIAID's commitment to high-quality clinical research is integral to improving health outcomes and informing policy decisions in the realm of infectious diseases and immunology.

Locations

Birmingham, Alabama, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0